TBTC sites added, Brazil among them

Four sites also get extra funds

Three new sites were announced last month by the Tuberculosis Trials Consortium (TBTC) of the Division of Tuberculosis Elimination (DTBE) of the Centers for Disease Control and Prevention (CDC):

• Emory University in Atlanta, where the principal investigator (PI) will be Susan Ray, MD, assistant professor of medicine in the division of infectious diseases.

• University of Southern California in San Diego, where the PI will be Antonino Catanzaro, MD, professor of medicine, the division of pulmonary and critical care medicine.

• Municipal Health Secretariat of Rio de Janeiro, Brazil, where the PI will be Afranio Kritsky, MD, an epidemiologist with the Federal University of Rio de Janeiro known internationally for his work in TB and TB/HIV research.

Additional funding has also been awarded to four current sites, including:

• University of North Texas in Fort Worth (where the PI is Stephen Weis, DO, professor of medicine, department of medicine, heath sciences center);

• Columbia University (where the PI is Neil Schluger, MD, assistant professor of medicine and clinical chief of the division of pulmonary and critical care medicine);

• University of Southern California/Los Angeles County (where the PI is Brenda Jones, MD, associate professor, department of internal medicine, division of infectious diseases);

• Audie L. Murphy Memorial Veterans Hospital in San Antonio (where the PI is Mark Weiner, MD, assistant professor, division of infectious diseases, department of medicine).

A grant was also awarded by the TBTC to the South African Research Council for starting a TBTC-like consortium of its own, says Rick O’Brien, MD, chief of the research and evaluation branch of the DTBE at the CDC. The South African entity, though it will function autonomously, will work closely in conjunction with the TBTC’s goals, O’Brien notes.

In other TBTC news, protocol was approved for Study 27. In addition, the 1,000th patient was enrolled in a TBTC study that looks at rifapentine for treatment of latent TB infection, putting enrollment for that massive trial at one-eighth of the way to completion.